TMZ + E7016
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Wild Type BRAF Stage IV Melanoma
Conditions
Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Trial Timeline
May 1, 2012 → Feb 1, 2014
NCT ID
NCT01605162About TMZ + E7016
TMZ + E7016 is a phase 2 stage product being developed by Eisai for Wild Type BRAF Stage IV Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01605162. Target conditions include Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma.
What happened to similar drugs?
0 of 1 similar drugs in Wild Type BRAF Stage IV Melanoma were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01605162 | Phase 2 | Terminated |
Competing Products
5 competing products in Wild Type BRAF Stage IV Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGM097 | Novartis | Phase 1 | 29 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 32 |
| Epirubicine, Oxaliplatin, Capecitabine, Panitumumab | Amgen | Phase 2 | 27 |
| Regorafenib + Temozolomide | Bayer | Phase 1 | 26 |
| STAT3 Inhibitor WP1066 | Moleculin Biotech | Phase 2 | 32 |